https://www.selleckchem.com/products/lgx818.html
https://www.selleckchem.com/products/lgx818.html
Doing work Storage Insert Results about the Tilt Aftereffect. Based on this finding, (R)-LMI was selected for pharmacological characterization. We have found that (R)-LMI is a CRF antagonist, inhibiting (1) the CRF-stimulated accumulation of cAMP in HEK 293 cells expressing the CRF1R, (2) the production of interleukins by adipocytes and (3) the proliferation rate of RAW 264.7 cells. (R)-LMI likely blocked agonist actions by interacting with the N-domain of CRF1R as suggested by data
Curtir
Comentario
Compartilhar
